Literature DB >> 19919727

S-adenosyl-L-methionine restores photoreceptor function following acute retinal ischemia.

Leith Moxon-Lester1, Kei Takamoto, Paul B Colditz, Nigel L Barnett.   

Abstract

The survival and function of retinal neurons is dependent on mitochondrial energy generation and its intracellular distribution by creatine kinase. Post ischemic disruption of retinal creatine synthesis, creatine kinase activity, or transport of creatine into neurons may impair retinal function. S-adenosyl-L-methionine (SAMe) is required for creatine synthesis, phosphatidylcholine and glutathione synthesis, and transducin methylation. These reactions are essential for photoreceptor function but may be downregulated after ischemia due to a reduction in SAMe. Our aim was to determine whether administration of SAMe after ischemia could improve retinal function. Unilateral retinal ischemia was induced in adult rats by increasing the intraocular pressure to 110 mm Hg for 60 min. Immediately after the ischemic insult, SAMe was injected into the vitreous (100 microM), followed by oral administration (69 mg/kg/day) for 5 or 10 days. Retinal function (electroretinography), histology, and creatine transporter (CRT-1) expression were analyzed. Photoreceptoral responses (R(mP3), S), rod and cone bipolar cell responses (PII), and oscillatory potentials were reduced by the ischemia/reperfusion insult. Although SAMe treatment ameliorated the ischemia-induced histological damage by day 5, there was no improvement in retinal function and the intensity of CRT-1 labeling in ischemic retinas was markedly reduced. However, 10 days after ischemia, a recovery in CRT-1 immunolabeling was evident and SAMe supplementation significantly restored photoreceptor function and rod PII responses. In conclusion, these data suggest that creatine transport and methylation reactions, such as creatine synthesis, may be compromised by an ischemic insult contributing to retinal dysfunction and injury. Oral SAMe supplementation after retinal ischemia may provide an effective, safe, and accessible neuroprotective strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19919727     DOI: 10.1017/S0952523809990241

Source DB:  PubMed          Journal:  Vis Neurosci        ISSN: 0952-5238            Impact factor:   3.241


  5 in total

Review 1.  X-linked creatine transporter deficiency: clinical aspects and pathophysiology.

Authors:  Jiddeke M van de Kamp; Grazia M Mancini; Gajja S Salomons
Journal:  J Inherit Metab Dis       Date:  2014-05-01       Impact factor: 4.982

2.  Conditional Müllercell ablation causes independent neuronal and vascular pathologies in a novel transgenic model.

Authors:  Weiyong Shen; Marcus Fruttiger; Ling Zhu; Sook H Chung; Nigel L Barnett; Joshua K Kirk; SoRa Lee; Nathan J Coorey; Murray Killingsworth; Larry S Sherman; Mark C Gillies
Journal:  J Neurosci       Date:  2012-11-07       Impact factor: 6.167

3.  Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect.

Authors:  Jiddeke M van de Kamp; Petra J W Pouwels; Femke K Aarsen; Leontine W ten Hoopen; Dirk L Knol; Johannes B de Klerk; Ireneus F de Coo; Jan G M Huijmans; Cornelis Jakobs; Marjo S van der Knaap; Gajja S Salomons; Grazia M S Mancini
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

4.  Metabolomic changes in the mouse retina after optic nerve injury.

Authors:  Kota Sato; Daisuke Saigusa; Ritsumi Saito; Amane Fujioka; Yurika Nakagawa; Koji M Nishiguchi; Taiki Kokubun; Ikuko N Motoike; Kazuichi Maruyama; Kazuko Omodaka; Yukihiro Shiga; Akira Uruno; Seizo Koshiba; Masayuki Yamamoto; Toru Nakazawa
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

5.  Changes of retinal structure and function in patients with internal carotid artery stenosis.

Authors:  Dong-Hui Wu; Lan-Ting Wu; Yan-Ling Wang; Jia-Lin Wang
Journal:  BMC Ophthalmol       Date:  2022-03-15       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.